Blog

How Patient Reported Outcomes Can Guide Trial Eligibility – ESMO

ESMO/LinkedIn

Jul 19, 2025, 14:29

How Patient Reported Outcomes Can Guide Trial Eligibility – ESMO

European Society for Medical Oncology shared a post on LinkedIn:

“In the era of Precision Medicine, waiting lists for alteration-matched studies are one of the key challenges in Early Drug Development.

Findings presented at ESMOTATAsia25 highlighted that Patient Reported Outcomes (PROs) may be a valid tool to select fitness for inclusion in a phase I Clinical Trial after 3 months.

Also presented were recommendations from the OPTIMISE-ROR project, which provides foundational guidance for triallists to systematically integrate PROs into dose-finding oncology trials.

Read the full commentary in the ESMO Daily Reporter.”

More posts featuring ESMO on OncoDaily.

cancer Early Drug Development ESMO ESMO Daily Reporter ESMOTATAsia25 European Society for Medical Oncology OncoDaily Oncology OPTIMISE-ROR project Precision Medicine

Marking One Year of Progress in IDH-Mutant Glioma Treatment - Servier Pharmaceuticals

James Whale Dies at 74: The Radio Icon’s Long Fight Against Kidney Cancer

A Pivotal Day for Geron

Top GU Immunotherapy Trials to Watch at ESMO 2025

Julie Gralow Received the 2025 NCG Lifetime Achievement Award in Oncology